-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

617.O2.6 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Molecular Features and Response to Treatment in AML

Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, clinical trials, adult, Translational Research, assays, bioinformatics, genomics, Combination therapy, Clinical Research, Diseases, Therapies, emerging technologies, Biological Processes, Myeloid Malignancies, survivorship, Technology and Procedures, Study Population, Human, Minimal Residual Disease , machine learning, molecular testing, omics technologies
Saturday, December 10, 2022: 4:00 PM-5:30 PM
388-390 (Ernest N. Morial Convention Center)
Moderators:
Alexandra Gomez-Arteaga, MD, Weill Cornell Medicine/New York Presbyterian Hospital and Shyam Ajay Patel, MD, PhD, University of Massachusetts Chan Medical School
Disclosures:
Patel: Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.
4:00 PM

Alberto Risueño, PhD1*, Wendy L. See, PhD2*, Courtney D. DiNardo, MD, MSCE3, Hartmut Döhner, MD4, Eytan Stein, MD5, Amir T. Fathi, MD6, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath7, Lynn Quek, MD PhD8*, Thomas Prebet, MD, PhD2*, Anita K. Gandhi, PhD9 and Maroof Hasan, MD9*

1BMS Center for Innovation and Translational Research Europe (CITRE), a Bristol-Myers Squibb Company, Seville, Spain
2Bristol Myers Squibb, Princeton, NJ
3The University of Texas MD Anderson Cancer Center, Houston, TX
4Ulm University Hospital, Ulm, Germany
5Memorial Sloan Kettering Cancer Center, New York, NY
6Director of Leukemia Program, Massachusetts General Hospital, Boston, MA
7University of Oxford and Oxford University Hospitals, Oxford, United Kingdom
8King's College Hospital NHS Foundation Trust, London, United Kingdom
9Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ

4:15 PM

Ali Bazarbachi, MD, PhD1, Jacques-Emmanuel Galimard, PhD2*, Myriam Labopin, MD3*, Iman Abou Dalle, MD4*, Bruno Lioure, MD5*, Johan A. Maertens, MD, PhD6*, Maija Itälä-Remes, MD, PhD7*, Maria Pilar Gallego Hernanz, MD, PhD8*, Gesine Bug, MD9*, Josep-Maria Ribera, MD, PhD10, Alain Gadisseur, MD, PhD11*, Christoph Schmid, MD12*, Xavier Poiré, MD, PhD13*, Manuel Jurado Chacón, MD14*, Frederic Baron, MD15*, Eolia Brissot16*, Arnon Nagler, MD17, Fabio Ciceri, MD18* and Mohamad Mohty, MD PhD19

1American University of Beirut Dept. of Medicine, Beirut, Lebanon
2Hôpital Saint-Antoine, EBMT Statistical Unit, Paris, France
3EBMT Statistical Unit, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France
4Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
5Département d'Hématologie et d'Oncologie, CHU Strasbourg, Strasbourg, France
6University Hospital Gasthuisberg, Leuven, Belgium
7Stem Cell Transplantation Unit, Turku University Hospital, Turku, Finland
8Poitiers University Hospital, Poitiers, France
9Goethe University Frankfurt, University Hospital, Dept. of Medicine, Hematology and Oncology, Frankfurt, Germany
10Clinical Hematology Department, Clinical Hematology Department. ICO_Hospital Germans Trias i Pujol. Josep Carreras Research Instoitute, Badalona, Spain
11Department of Haematology, Antwerp University Hospital, Edegem, Belgium
12Department of Hematology and Oncology / Stem Cell Transplantation, Augsburg University Hospital and Medical Faculty, Augsburg, Germany
13Section of Hematology, Cliniques Universitaires St-Luc, Brussels, Brussels, Belgium
14Hematology Department, Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain
15University of Liege, Liege, Belgium
16Service d'Hématologie Clinique et de Thérapie Cellulaire, Hospital Saint Antoine, Paris Cedex 12, France
17Hematology and Bone Marrow Transplant Unit, Chaim Sheba Medical Center, Tel Hashomer, Israel
18Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
19EBMT Paris study office / CEREST-TC, Paris, France, Department of Hematology, Saint Antoine Hospital, Paris, France, INSERM UMR 938, Sorbonne University, Paris, France

4:30 PM

Laurène Fenwarth, MD, MSc1,2*, Loïc Vasseur3*, Nicolas Duployez, PharmD, PhD1,2*, Claude Gardin, MD4*, Christine Terré, PharmD, PhD5*, Juliette Lambert, MD, PhD6*, Stéphane de Botton, MD, PhD7*, Karine Celli-Lebras, CRA8*, Pascal Turlure, MD9*, Thomas Cluzeau, MD, PhD10, Thorsten Braun, MD, PhD4, Xavier Thomas, MD, PhD11, Christian Recher, MD12, Sylvain Chantepie, MD13*, Cécile Pautas, MD14*, Hervé Dombret, MD, PhD15, Claude Preudhomme, PharmD, PhD1,2 and Raphael Itzykson, MD, PhD16,17

1Laboratory of Hematology, CHU Lille, Lille, France
2UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Univ. Lille, CNRS, Inserm, CHU Lille, Lille, France
3Adolescents and Young Adults Hematology Department, St-Louis University Hospital, AP-HP, Paris, France
4Hematology Department, Avicenne Hospital, Bobigny, France
5Laboratory of Hematology, Centre hospitalier de Versailles, Le Chesnay, France
6Service d'Hématologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France
7Département d’hématologie et Département d’innovation thérapeutique, Gustave Roussy, Villejuif, France
8ALFA coordination, Saint-Louis University Hospital, Paris, France
9Department of Clinical Hematology, Limoges University Hospital, Limoges, France
10Département d'Hématologie Clinique, Université Côte d'Azur, CHU Nice, Nice, Provence Alpes Cote d'Azur, France
11Hematology Department, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre-Benite, France
12Service d'Hématologie, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
13Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen Cedex 9, France
14Hematology Department, Henri Mondor University Hospital, Créteil, France
15Division of Hematology, EA3518 Saint-Louis Institute for Research, Hôpital Saint-Louis, APHP, University of Paris, Paris, France, Paris, France
16Department of Hematology, Hôpital Saint-Louis, Paris, France
17UMR7212/U944, Institut National de la Santé et de la Recherche Médicale, Saint-Louis Institute, University Paris 7, Paris, France

4:45 PM

Alberto Hernández Sánchez, MD1,2*, Angela Villaverde Ramiro2,3*, Eric Sträng, PhD4*, Castellani Gastone, PhD5*, Caroline A. Heckman, PhD6, Jurjen Versluis, MD, PhD7*, María Abáigar3,8*, Marta Anna Sobas, MD, PhD9*, Raúl Azibeiro Melchor10*, Axel Benner11*, Peter JM Valk, PhD12, Klaus H Metzeler, MD13, Teresa González, PhD2,3*, Daniele Dall'Olio, PhD14*, Jesse M. Tettero15*, Javier Martinez Elicegui2,3*, Joaquín Martínez-López, MD, PhD16*, Marta Pratcorona, MD17*, Frederik Damm, MD18*, Ken I Mills, BSc, PhD, FRCPath19, Christian Thiede, MD20, Maria Teresa Voso, MD21, Guillermo Sanz, MD, PhD22,23, Konstanze Döhner, MD24, Michael Heuser, MD25, Torsten Haferlach, MD26, Amin T. Turki, MD27, Rubén Villoria Medina28*, Michel van Speybroeck, MSc29*, Renate Schulze-Rath30*, Martje Barbus, PhD31*, John E Butler32*, Jesús María Hernández-Rivas, MD, PhD1,2,3, Brian Huntly, MB ChB, FRCPath, FMedSci, PhD33, Gert Ossenkoppele, MD34, Hartmut Döhner, MD35 and Lars Bullinger, MD36

1Hematology Department, University Hospital of Salamanca, Salamanca, Spain
2Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
3Cancer Research Center of Salamanca (USAL-CSIC), Salamanca, Spain
4Charité Universitätsmedizin Berlin, Berlin, Germany
5DIMES, University of Bologna, Bologna, Italy
6Institute for Molecular Medicine Finland, Institute For Molecular Medicine Finland FIMM, Helsinki, Finland
7Erasmus University Medical Center Cancer Institute, Rotterdam, Rotterdam, Netherlands
8Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
9Department of Hematology, Blood Neoplasm and Bone Marrow Transplantation, Hosp. Clinico Univ. de Santiago de Compostela, Santiago de Compostela, Spain
10University Hospital of Burgos, Burgos, Spain
11Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
12Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands
13University of Leipzig, Germany, Leipzig, Germany
14University of Bologna, Bologna, Italy
15Department of Hematology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
16Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
17Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
18Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
19Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom
20University of Technics Dresden Medical Dept., Dresden, Germany
21University Tor Vergata, Rome, Italy
22CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
23Hospital Universitario y Politécnico La Fe, Valencia, Spain
24Division of Hematology and Oncology, University Hospital Ulm, Ulm, Germany
25Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
26MLL Munich Leukemia Laboratory, Munich, Germany
27Department of Hematology and Stem Cell Transplantation, University Hospital of Essen, Essen, Germany
28GMV Innovating Solutions, Valencia, Spain
29Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium
30Bayer AG, Pharmaceuticals Division, Berlin, Berlin, Germany
31AbbVie Deutschland GmbH & Co KG, Wiesbaden, DEU
32Bayer AG, Pharmaceuticals Division, Berlin, Germany
33Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, ENG, United Kingdom
34Amsterdam University Medical Center, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands
35Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
36Department of Hematology, Oncology, and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

5:00 PM

Sydney Fobare1, Shelley Orwick, BS1*, Jessica Kohlschmidt, PhD2,3, Tom Sesterhenn4*, Krzysztof Mrózek, MD, PhD5, Ben Wronowski4*, Megan Johnstone, PhD4*, Andrew J. Carroll, PhD6, Richard M. Stone, MD7, Eunice S. Wang, MD8, Jonathan E. Kolitz, MD9, Bayard L. Powell, MD10, John P Perentesis, MD11, Ann-Kathrin Eisfeld, MD1,12, Erin Hertlein, PhD4 and John C. Byrd, MD4

1Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
2Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus
3Alliance Statistics and Data Management Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH
4Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
5Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH
6Department of Genetics, University of Alabama at Birmingham, Birmingham, AL
7Dana-Farber Cancer Institute, Boston, MA
8Roswell Park Comprehensive Cancer Center, Buffalo, NY
9Monter Cancer Center, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY
10Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC
11Cancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, OH
12Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University, Columbus, OH

5:15 PM

Alireza Torabi, MD, PhD1*, Todd A. Alonzo, PhD2,3*, Megan Othus, PhD4, Robert B. Gerbing, MA2*, Yi-Cheng Wang, MS2*, Rhonda E. Ries, MA5*, Jerald P. Radich, MD5, Frederick R. Appelbaum, MD6, Kristin O’Dwyer, MD7*, Harry P. Erba, MD, PhD8, Martin S. Tallman, MD9,10, Mark R. Litzow, MD11, Ehab L. Atallah, MD12, Selina M. Luger, MD, FRCPC13, Anders E. Kolb, MD14, Omar Abdel-Wahab, MD15, Derek Stirewalt, MD16, Ross L. Levine, MD17, Elisabeth Paietta, PhD18 and Soheil Meshinchi, M.D., Ph.D.19

1Pathology/Hematopathology, University of Washington, Seattle, WA
2Children's Oncology Group, Monrovia, CA
3Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA
4Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
5Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
6Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
7University of Rochester, Rochester, NY
8Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC
9Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
10Department of Medicine, Weill Cornell Medical College, New York, NY
11Division of Hematology, Mayo Clinic, Rochester, MN
12Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
13Cellular Therapy and Transplantation, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
14Division of Oncology, Nemours/Alfred I. duPont Hospital For Children, Wilmington, DE
15Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
16Departments of Oncology and Hematology, Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA
17Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
18Cancer Center, Montefiore Medical Center, Bronx, NY
19Fred Hutchinson Cancer Center, Seattle, WA

*signifies non-member of ASH